New macrolide, lincosaminide and streptogramin B antibiotics

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 10, 2010, Pages 1343-1357

  Kirst, Herbert A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

antibiotic; erythromycin; ketolide; lincosaminide; macrolide; MLS Bclass; streptogramin

Indexed keywords

2,3 ANHYDROLIDE; 9 ACETYLIMINO 3 DEHEXAPYRANOSYLOXY 9 DEOXO 3 OXO 6 O,11 O [2 [6 (1 PYRAZOLYL) 3 PYRIDINYLMETHOXYIMINO]PROPYLENE]ERYTHROMYCIN; AZITHROMYCIN; BAL 19403; CEM 101; CETHROMYCIN; CLADINOSE; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DESOSAMINE; EDP 182; ERYTHROMYCIN; ERYTHROMYCIN DERIVATIVE; JOSAMYCIN; K 1325; KETOLIDE; KITASAMYCIN; LINCOMYCIN; LINCOSAMIDE; LINOPRISTIN; MACROLIDE; MIKAMYCIN B; MIRINCAMYCIN; NXL 103; PF 04287881; TE 802; TELITHROMYCIN; TYLOSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIMICROBIAL ACTIVITY; CLINICAL TRIAL; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LIVER TOXICITY; REVIEW; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG DISCOVERY; DRUG RESISTANCE, MICROBIAL; HUMANS; LINCOSAMIDES; MACROLIDES; STREPTOGRAMIN B;

EID: 77956656787     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.505921     Document Type: Review

References (116)

1. Kirst HA. Aminoglycoside, macrolide, glycopeptide, and miscellaneous antibacterial antibiotics. In: Wolff ME, editor, Burger's medicinal chemistry and drug discovery. 5th edition. Volume 2. John Wiley & Sons; 1996. p. 463-525
2. Kaneko T, Dougherty TJ, Magee TV. Macrolide antibiotics. In: Taylor JB, Triggle DJ, editors, Comprehensive medicinal chemistry II. Volume 7. Elsevier; 2007. p. 519-566
3. Kirst HA. Antibiotics (macrolides). In: Seidel A, editor, Kirk-Othmer encyclopedia of chemical technology. 5th edition. Volume 15. John Wiley & Sons; 2005. p. 271-320
4. Sivapalasingam S, Steigbigel NH. Macrolides, clindamycin, and ketolides. In: Mandell GL, Bennett JE, Dolin R, editors, Mandell, Douglas, and Bennett's principles and practice of infectious diseases (Chapter 30). 7th edition. Volume 1. Churchill Livingstone; 2009
5. Mulazimoglu L, Tulkens PM, Van Bambeke F. Macrolides. In: Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, editors, Antimicrobial therapy and vaccines. 2nd edition. Volume 2. ESun Technologies; 2005. p. 243-280
6. Agouridas C, Benedetti Y, Denis A, et al. Ketolides, a new distinct semi-synthetic class of macrolides. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Orlando, FL; 1994. p. F-164
7. Agouridas C, Benedetti Y, Denis A, et al. Ketolides, a new distinct class of macrolide antibacterials. Synthesis and structural characteristics of RU 004. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; 1995. p. F-157
8. Bryskier A, Denis A. Ketolides: novel antibacterial agents designed to overcome resistance to erythromycin A within gram-positive cocci. In: Schonfeld W, Kirst HA, editors, Macrolide antibiotics.Birkhauser Verlag; 2002. p. 97-140
9. Reinert RR. Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother 2004;53:918-927
10. Wellington K, Noble S. Telithromycin. Drugs 2004;64:1683-1694
11. Zhanel GG, Neuhauser MM. Ketolides (telithromycin, cethromycin). In: Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, editors, Antimicrobial therapy and vaccines. 2nd edition. Volume 2. ESun Technologies; 2005. p. 201-222
12. Van Bambeke F, Harms JM, Van Laethem Y, Tulkens PM. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. Expert Opin Pharmacother 2008;9:267-283
13. Kaye D. U. S. limits use of risky Sanofi antibiotic Ketek. Clin Infect Dis 2007;44:iv
14. Soreth J, Cox E, Kweder S, et al. Ketek-the FDA perspective. N Engl J Med 2007;356:1675-1676
15. Ross DB. The FDA and the case of Ketek. N Engl J Med 2007;356:1601-1604
16. Hammerschlag MR, Sharma R. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Expert Opin Investig Drugs 2008;17:387-400
17. Anonymous. Cethromycin: A-195773, A-195773-0, A-1957730, Abbott-195773, ABT 773. Drugs 2007;8:95-102 Available from: http://www.advancedlifesciences.com
18. Wang G, Niu D, Qiu Y-L, et al. Synthesis of novel 6,11-O-bridged bicyclic ketolides via a palladium-catalyzed bis-allylation. Org Lett 2004;6:4455-4458
19. Jiang L-J, Wang M, Or YS. Pharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers. Antimicrob Agents Chemother 2009;53:1786-1792
20. Jiang L-J, Or YS. Pharmacokinetics of EDP-420 after multiple oral doses in healthy adult volunteers and in a bioequivalence study. Antimicrob Agents Chemother 2009;53:3218-3225
21. Furuie H, Saisho Y, Yoshikawa T, Shimada J. Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. Antimicrob Agents Chemother 2010;54:866-870 Available from: http://www.enanta.com
22. Liang C-H, Yao S, Chiu Y-H, et al. Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. Bioorg Med Chem Lett 2005;15:1307-1310
23. Romero A, Liang C-H, Chiu Y-H, et al. An efficient entry to new sugar modified ketolide antibiotics. Tetrahedron Lett 2005;46:1483-1487
24. Optimer Pharmaceuticals, Inc. Novel antibacterial agents. WO2004080391; 2004
25. Woosley LN, Castanheira M, Jones RN. CEM-101 activity against gram-positive organisms. Antimicrob Agents Chemother 2010;54:2182-2187
26. McGhee P, Clark C, Kosowska-Shick KM, et al. In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms. Antimicrob Agents Chemother 2010;54:230-238 Available from: http://www.cempra.com
27. Bertrand D, Bertrand S, Fernandes P. Proposed mechanisms to explain the unusual visual disturbances associated with telithromycin. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. A1-580
28. Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents. WO2009055557; 2009
29. Mullins LM, Huband MD, McCurdy SP, et al. In vitro and in vivo antibacterial activity of PF-04287881: a new ketolide antimicrobial against recent bacterial clinical isolates. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. F1-2042
30. Pfizer Products, Inc. Erythromycin-based macrolides. WO2008110918; 2008
31. Magee TV, Ripp SL, Li B, et al. Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections. J Med Chem 2009;52:7446-7457 Available from: http://www.pfizer.com
32. Flanagan ME, Chupak L, Dougherty TJ, et al. New series of azetidinyl ketolide sulfonamides: structure activity relationships and identification of PF-03438011 and PF-03438012. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. F1-2041
33. Pfizer Products, Inc. Macrolides. WO2006067589; 2006
34. Kouvela EC, Kalpaxis DL, Wilson DN, Dinos GP. Distinct mode of interaction of a novel ketolide antibiotic that displays enhanced antimicrobial activity. Antimicrob Agents Chemother 2009;53:1411-1419
35. Kosan Biosciences, Inc. Amido macrolides. WO2003061671; 2003
36. Kosan Biosciences, Inc. 7-Quinolyl ketolide antibacterial agents. WO2007/070536; 2007
37. Ward SL, Desai RP, Hu Z, et al. Precursor-directed biosynthesis of 6-deoxyerythronolide B analogues is improved by removal of the initial catalytic sites of the polyketide synthase. J Ind Microbiol Biotechnol 2007;34:9-15
38. Pal S. A journey across the sequential development of macrolides and ketolides related to erythromycin. Tetrahedron 2006;62:3171-3200
39. Xu P, Liu L, Chen X-Z, et al. Synthesis of novel macrolide derivatives with imidazo[4,5-b]pyridinyl sulfur contained alkyl side chains and their antibacterial activity. Bioorg Med Chem Lett 2009;19:4079-4083
40. Kaneko T, Romero K, Li B, Buzon R. Novel tethers in ketolide antibiotics. Bioorg Med Chem Lett 2007;17:5049-5053
41. Taisho Pharmaceutical Co., Ltd. 2-Fluoro-6-O-substituted ketolide derivative. WO2005087787; 2005
42. Taisho Pharmaceutical Co., Ltd. 6-O-Substituted ketolide derivatives. WO2005075495; 2005
43. Bhateja P, Barman T, Singhal S, et al. In vitro and in vivo efficacy of novel ketolide RBx YSB 93019 and comparison with telithromycin. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. F1-2046
44. Ranbaxy Laboratories Ltd. Ketolide derivatives as antibacterial agents. WO2007060518; 2007
45. Pfizer, Inc. Macrolide antibiotics. US6809080; 2004
46. Kaneko T, McMillen W, Lynch MK. Synthesis and antibacterial activity of C11, C12-cyclic urea analogues of ketolides. Bioorg Med Chem Lett 2007;17:5013-5018
47. Glaxo Group Ltd. Macrolide antibiotics. WO2002050092; 2002
48. Andreotti D, Bientinesi I, Biondi S, et al. A novel ketolide class: synthesis and antibacterial activity of a lead compound. Bioorg Med Chem Lett 2007;17:5265-5269
49. Hunziker D, Wyss P, Angehrn P, et al. Novel ketolide antibiotics with a fused five-membered lactone ring-synthesis, physicochemical and antimicrobial properties. Bioorg Med Chem 2004;12:3503-3519
50. Enanta Pharmaceuticals, Inc. Novel 11,12-substituted lactone ketolide derivatives having antibacterial activity. WO2004016634; 2004
51. Alpharma APS. 10-Substituted macrolide antibiotics. WO2004056843; 2004
52. Undheim K, Gunnes S. Chemoselective synthesis of erythromycin A ketolides substituted in the C10-methyl group. Bioorg Med Chem 2007;15:119-129
53. Lin X, Rico AC, Chu DT, et al. Synthesis and antibacterial activity of C12 des-methyl ketolides. Bioorg Med Chem Lett 2006;16:4692-4696
54. Burger MT, Hiebert C, Seid M, et al. Synthesis and antibacterial activity of novel C12 ethyl ketolides. Bioorg Med Chem 2006;14:5592-5604
55. Burger MT, Lin X, Chu DT, et al. Synthesis and antibacterial activity of novel C12 vinyl ketolides. J Med Chem 2006;49:1730-1743
56. Enanta Pharmaceuticals, Inc. 6,11 Bicyclic ketolide derivatives. WO2003097659; 2003
57. Enanta Pharmaceuticals, Inc. Processes for the preparation of O-(2-aminobenzo [D]oxazol-5-yl methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182. US7563877; 2009
58. Enanta Pharmaceuticals, Inc. Processes for the preparation of 2-fluoro 6-11 bicyclic erythromycin derivatives. WO2009137787; 2009
59. Enanta Pharmaceuticals, Inc. Processes for the preparation of O-[5-[4-amino-thiazol-2-yl]-pyridin-2-ylmethyl]-hydroxylamine. WO2009137739; 2009
60. Enanta Pharmaceuticals, Inc. 6, 11-4-Carbon bridged erythromycin derivatives. WO2004011009; 2004
61. Enanta Pharmaceuticals, Inc. 6, 11-Bridged tricyclic macrolides. WO2007044927; 2007
62. Ono T, Kashimura M, Suzuki K, et al. In vitro and in vivo antibacterial activities of the tricyclic ketolide TE-802 and its analogs. J Antibiot 2004;57:518-527
63. Enanta Pharmaceuticals, Inc. 3, 6-Bicyclolides. WO2006063039; 2006
64. Gai Y, Tang D, Xu G, et al. Synthesis of 3,6-bicyclolides: a novel class of macrolide antibiotics. Bioorg Med Chem Lett 2008;18:6315-6318
65. Tang D, Gai Y, Polemeropoulos A, et al. Design, synthesis, and antibacterial activities of novel 3,6-bicyclolide oximes: length optimization and zero carbon linker oximes. Bioorg Med Chem Lett 2008;18:5078-5082
66. Enanta Pharmaceuticals, Inc. 11, 12-Lactone bicyclolides. WO2006065721; 2006
67. Enanta Pharmaceuticals, Inc. 3,6,11-Tricyclolide. WO2007115278; 2007
68. Enanta Pharmaceuticals, Inc. Tetracyclic bicyclolides. WO2006065743; 2006
69. Mutak S. Azalides from azithromycin to new azalide derivatives. J Antibiot 2007;60:85-122
70. Basnet DB, Park JW, Yoon YJ. Combinatorial biosynthesis of 5-O-desosaminyl erythronolide A as a potent precursor of ketolide antibiotics. J Biotechnol 2008;135:92-96
71. Xu P, Liu L, Jin Z, Lei P. Synthesis and antibacterial activity of derivatives of 6-O-allylic acylides. Bioorg Med Chem Lett 2007;17:3330-3334
72. Ranbaxy Laboratories Ltd. Erythromycin A derivatives as antibacterial agents. WO2006035301; 2006
73. Liang J-H, Wang Y-Y, Zhu D-Y, et al. Design, synthesis and antibacterial activity of a novel alkylide: 3-O-(3-aryl-propenyl)clarithromycin derivatives. J Antibiot 2009;62:605-611
74. Enanta Pharmaceuticals, Inc. Novel anhydrolide derivatives having antibacterial activity. WO2004069854; 2004
75. Takashima H. Structural consideration of macrolide antibiotics in relation to the ribosomal interaction and drug design. Curr Topics Med Chem 2003;3:991-999
76. Ma C, Liu Z, Song H, et al. Synthesis and antibacterial activity of novel 11,12-cyclic carbonate azithromycin 4¢¢-O-carbamate derivatives. J Antibiot 2010;63:3-8
77. Ma S, Ma R, Liu Z, et al. Synthesis and antibacterial activity of novel 15-membered macrolide derivatives: 4¢¢-carbamate, 11,12-cyclic carbonate-4¢¢-carbamate and 11,4¢¢-di-O-arylcarbamoyl analogs of azithromycin. Eur J Med Chem 2009;44:4010-4020
78. Stimac V, Alihodzic S, Lazarevski G, et al. Synthesis and biological properties of 4¢¢-O-acyl derivatives of 8a-aza-8a-homoerythromycin. J Antibiot 2009;62:133-144
79. Xu P, Liu L, Jin Z-P, et al. Synthesis and antibacterial activity of 4¢¢-O-heteroarylcarbamoyl derivatives of macrolide. Bioorg Med Chem Lett 2008;18:5507-5511
80. Wimberly BT. The use of ribosomal crystal structures in antibiotic drug design. Curr Opin Investig Drugs 2009;10:750-765
81. Burak E, Bortolon E, Franceschi F, et al. Enhanced macrolides: optimized molecular properties for oral exposure. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. F1-2049
82. Kanyo Z, Bhattacharjee A, Chen S, et al. Enhanced macrolides: overcoming resistance by improving target affinity. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. F1-2050
83. Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same. WO2008143730; 2008
84. Rib-X Pharmaceuticals, Inc. Macrolide compounds and methods of making and using the same. WO2008106226; 2008
85. Hanselmann R, Job GE, Johnson G, et al. Synthesis of an antibacterial compound containing a 1,4-substituted 1H-1,2,3-triazole: a scaleable alternative to the "click" reaction. Org Proc. Res Dev 2010;14:152-158
86. Heggelund A, Undheim K. Preparation of cyclic 2',3'-carbamate derivatives of erythromycin macrolide antibiotics. Bioorg Med Chem 2007;15:3266-3277
87. Alpharma APS. Erythromycin derivatives as antibacterial agents. WO2006074962; 2006
88. Dreier J, Amantea E, Kellenberger L, Page MGP. Activity of the novel macrolide BAL19403 against ribosomes from erythromycin-resistant Propionibacterium acnes. Antimicrob Agents Chemother 2007;51:4361-4365
89. Falzari K, Zhu Z, Pan D, et al. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49:1447-1454
90. Krajacic MB, Novak P, Dumic M, et al. Novel ureas and thioureas of 15-membered azalides with antibacterial activity against key respiratory pathogens. Eur J Med Chem 2009;44:3459-3470
91. Creemer LC, Toth JE, Kirst HA. Synthesis and in vitro antimicrobial activity of 3-keto 16-membered macrolides derived from tylosin. J Antibiot 2002;55:427-436
92. Mutak S, Marsic N, Kramaric MD, Pavlovic D. Semisynthetic macrolide antibacterials derived from tylosin. Synthesis and structure-activity relationships of novel desmycosin analogues. J Med Chem 2004;47:411-431
93. Terui Y, Kinoshita K, Kaneda Y, et al. Synthesis of 2-methyl 16-membered macrolide derived from tylosin. J Antibiot 2006;59:98-104
94. Yang B, Zollner T, Gebhardt P, et al. Preparation and biological evaluation of novel leucomycin analogs derived from nitroso Diels-Alder reactions. Org Biomol Chem 2010;8:691-697
95. Meiji Seika Kaisha, Ltd. 12-Oxy-13-amino-containing 16-membered cyclic macrolide derivative and process for producing the same. WO2006073172; 2006
96. Miura T, Kurihara K, Furuuchi T, et al. Novel 16-membered macrolides modified at C-12 and C-13 positions of midecamycin A1 and miokamycin. Part 1. Bioorg Med Chem 2008;16:3985-4002
97. Furuuchi T, Miura T, Kurihara K, et al. Design and synthesis of novel leucomycin analogues modified at the C-3 position. Part II. Bioorg Med Chem 2008;16:4401-4418
98. Meiji Seika Kaisha, Ltd. Novel 16-membered cyclic 4¢¢-O- carbamoyl azalide derivative and process for producing the same. WO2007069555; 2007
99. Miura T, Kanemoto K, Natsume S, et al. Novel azalides derived from 16-membered macrolides. Part II. Bioorg Med Chem 2008;16:10129-10156
100. Miura T, Natsume S, Kanemoto K, et al. Novel azalides derived from 16-membered macrolides. J Antibiot 2007;60:407-435
101. Enanta Pharmaceuticals, Inc. 3,6-Bridged tylosin derivatives. WO2008019240; 2008
102. Intervet International B. V. Macrolide solid-state forms. WO2009013351; 2009
103. Intervet International B. V. Macrolide synthesis process. WO2008012343; 2008
104. Meiji Seika Kaisha, Ltd. Lincomycin derivatives and antibacterial agents containing the same as the active ingredient. WO2008146917; 2008
105. Meiji Seika Kaisha, Ltd. Lincomycin derivative and antibacterial agent comprising the same as active ingredient. WO2008146919; 2008
106. Meiji Seika Kaisha, Ltd. Lincomycin derivative and antibacterial agent containing the same as active ingredient. WO2007066805; 2007
107. Ulanova D, Novotna J, Smutna Y, et al. Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci. Antimicrob Agents Chemother 2010;54:927-930
108. Held J, Westerman R, Kremsner PG, Mordmuller B. In vitro activity of mirincamycin (U24729A) against Plasmodium falciparum isolates in Gabon. Antimicrob Agents Chemother 2010;54:540-542
109. Lee VJ. Anti-gram positive agents of natural product origins. In: Taylor JB, Triggle DJ, editors, Comprehensive medicinal chemistry II. Volume 7. Elsevier; 2007. p. 660-664
110. Bacque E, Barriere J-C, Berthaud N. Recent progress in the field of antibacterial pristinamycins. Curr Med Chem Anti Infect Agents 2005;4:185-217
111. Rangaraju M, Tarral A, Merdjan H, et al. Optimization of the linopristin/ flopristin dose ratio in NXL103. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. A1-1943
112. Rangaraju M, Rabie W, Ponte N, et al. A phase II double-blind, double-dummy, multicenter study of two doses of linopristin/flopristin (NXL103) vs. amoxicillin in the treatment of mild to moderate community acquired pneumonia (CAP) in adults. 49th Interscience Conference on Antimicrobial Agents Chemotherapy. San Francisco, CA; 2009. p. L1-336
113. Politano AD, Sawyer RG. NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA. Curr Opin Investig Drugs 2010;11:225-236
114. Amsden GW. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005;55:10-21
115. Lopez-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol 2008;8:286-291
116. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008;31:12-20